Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RespirOndine

Financiado

Cerrado

Development of life changing drugs for patients suffering from severe and fatal...

Development of life changing drugs for patients suffering from severe and fatal neurological disorders AtmosR is a start-up whose mission is to develop innovative therapeutic solutions for patients suffering from severe and often fatal disorders of the central nervous system. Our company has established a technology in order to de... ver más

31/12/2023

ATMOSR

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

ATMOSR No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-31

HORIZON-EIE-2022-SCALEUP-02-02: Women TechEU Expected Outcome:Project results are expected to contribute to the following expected outcomes:

Innovación

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ATMOSR

75.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 6 meses Fecha Inicio: 2023-06-01
Fecha Fin: 2023-12-31

Líder del proyecto

ATMOSR No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 75K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto AtmosR is a start-up whose mission is to develop innovative therapeutic solutions for patients suffering from severe and often fatal disorders of the central nervous system. Our company has established a technology in order to develop treatments for aggregate pathologies (such as ALS, Kennedy disease, Multisystem Atrophy, Parkinson, Huntington...) which represent a major health problem considering the high number of patients worldwide and the high unmet medical need. The first disorder targeted by AtmosR is Congenital Central Hypoventilation Syndrome (CCHS), a rare genetic syndrome which presents as its main symptom severe periods of hypoventilation. Patients are kept alive thanks to mechanical ventilation administered through a tracheostomy. Our goal is to develop a drug that will be life changing for patients and their families, liberating them from the machine, lifting the vital risk and allowing them to live independently. Our team consists of multidisciplinary profiles with experience in both drug development, particularly in the field of rare diseases, and in business management. As a spin-off of the french CCHS patient organization, we work in close cooperation with the international academic experts in CCHS, especially in France, Italy and Israël. We have identified a Hit compound ATS-003 that is active in both in vitro and in vivo CCHS robust models and we have optimized the compound thanks to a chemistry program in order to improve its efficiency and lower its toxicity for a better long term use tolerance. We are starting regulatory preclinical work in 2023 with this new Lead compound and have planned the first clinical trials by mid 2025 and an early drug access for patients in 2027. In addition to CCHS, we have identified several disorders with similar protein aggregation mechanisms. We plan to test and develop our Lead compound for other more common disorders and the purpose of this project is to idententify the most promising one for our Lead.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores